Study of Olverembatinib (HQP1351) in Patients With CP-CML

Clinical trial NCT06423911 · RECRUITING

Trial details

NCT number: NCT06423911
Sponsor: Ascentage Pharma Group Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia CML CML, Chronic Phase

Start date: 2024-02-05
Primary completion: 2025-12-01
Enrollment: 285

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.